Regenxbio (RGNX) said Tuesday that the US Food and Drug Administration has accepted and granted priority review to a biologics license application for clemidsogene lanparvovec, or RGX-121, to potentially treat mucopolysaccharidosis II, also known as Hunter syndrome.
The FDA has set a target action date of Nov. 9, the company said.
The drug earlier received orphan drug product, rare pediatric disease, fast track, and regenerative medicine advanced therapy designations from the FDA as well as an advanced therapy medicinal products classification from the European Medicines Agency, Regenxbio said.
Hunter syndrome is a rare genetic disease which can lead to severe developmental delays in children.
Shares of Regenxbio were up more than 6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.